DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance
AUTOR(ES)
Sousa, Juliana Ferreira de
FONTE
Genet. Mol. Biol.
DATA DE PUBLICAÇÃO
13/12/2019
RESUMO
Abstract Glioblastoma (GBM) is the most common and malignant type of primary brain tumor, showing rapid development and resistance to therapies. On average, patients survive 14.6 months after diagnosis and less than 5% survive five years or more. Several pieces of evidence have suggested that the DNA damage signaling and repair activities are directly correlated with GBM phenotype and exhibit opposite functions in cancer establishment and progression. The functions of these pathways appear to present a dual role in tumorigenesis and cancer progression. Activation and/or overexpression of ATRX, ATM and RAD51 genes were extensively characterized as barriers for GBM initiation, but paradoxically the exacerbated activity of these genes was further associated with cancer progression to more aggressive stages. Excessive amounts of other DNA repair proteins, namely HJURP, EXO1, NEIL3, BRCA2, and BRIP, have also been connected to proliferative competence, resistance and poor prognosis. This scenario suggests that these networks help tumor cells to manage replicative stress and treatment-induced damage, diminishing genome instability and conferring therapy resistance. Finally, in this review we address promising new drugs and therapeutic approaches with potential to improve patient survival. However, despite all technological advances, the prognosis is still dismal and further research is needed to dissect such complex mechanisms.
Documentos Relacionados
- Resistance of human cells to tumorigenesis induced by cloned transforming genes.
- DNA repair pathways and cisplatin resistance: an intimate relationship
- Role of DNA repair in Bacillus subtilis spore resistance.
- Suppression of human DNA alkylation-repair defects by Escherichia coli DNA-repair genes.
- Derepression of specific genes promotes DNA repair and mutagenesis in Escherichia coli.